ArticleJTCVS open2023

Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome.

Rachel E Wittenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.